Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 58Active not recruiting 17Recruiting 14Terminated 9Unknown 6Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 103INDUSTRY 28NIH 11NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 17Gynecologic 15Breast 14Thoracic 13Lymphoid 13Sarcoma 10Head & Neck 10Other hematologic neoplasm 9CNS 9Genitourinary 8Dermatologic 5Endocrine 3Other solid neoplasm 2Myeloid 2Tumor-Agnostic 1Plasma cell 1Other 1

Conditions

Multiple Myeloma 1

Interventions

Thalidomide 1Microarray Analysis 1Melphalan 1Lenalidomide 1Gene Expression Profiling 1Etoposide 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × Plasma cell × Clear all
NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡